July 9, 2025

PreSize® Neurovascular Landmark Clinical Impact Trial Receives ESMINT Endorsement

The clinical impact trial of Oxford Heartbeat's decision-support software, PreSize® Neurovascular, has been endorsed by The European Society of Minimally Invasive Neurological Therapy (ESMINT).
Words by
Photography
Posted
July 9, 2025
Share ON SOCIAL
The independently run trial aims to quantify the benefits of using PreSize in clinical practice.
ESMINT is a leading authority in neurointerventional medicine, so endorsement highlights the trial's robust methodology, and validates its scientifice and clinical relevance.
Endorsement also reinforces Oxford Hearbeat's mission to set the standard of evidence generation for use of decision-support software in neuroradiology.

London, 9th July 2025 - Oxford Heartbeat is excited to share that the clinical impact trial of its decision-support software PreSize® Neurovascular has been endorsed by The European Society of Minimally Invasive Neurological Therapy (ESMINT). ESMINT endorsement signifies strong support from a leading authority in neurointerventional medicine, reinforcing Oxford Heartbeat’s mission to set a new standard of evidence generation for the use of decision-support software in neuroradiology. 

This is yet another piece of fantastic news from the prospective, multi-centre trial, which aims to quantify the benefits of using PreSize in clinical practice. The trial is being independently run by Imperial Clinical Trials Unit (ICTU) and successfully completed patient recruitment of 103 participants last year, involving 9 UK hospitals and 22 interventional neuroradiologists. Funded by the UK’s National Institute for Health and Care Research’s (NIHR) prestigious AI in Health and Care Award and featured on BBC Click, this is the first trial of its kind for decision-support software in the neurovascular space.

The trial’s Chief Investigator, Professor Dr Tufail Patankar, from Barking, Havering and Redbridge University Hospitals NHS Trust, explained the significance of ESMINT endorsement, saying “ESMINT plays a crucial role in shaping clinical practice in neurointervention, so their endorsement of PreSize trial highlights the trial’s robust methodology, and validates its scientific and clinical relevance.” 

The 103 patients included in the registered study were diagnosed with a cerebral aneurysm and scheduled to be treated minimally invasively. For each patient, their treatment was planned twice - both with and without PreSize - and information was collected on the accuracy of PreSize, surgical efficiency metrics, and patient outcomes. The results of the trial will be used to compare clinical decision making with traditional planning methods vs. with PreSize. The data is currently undergoing independent analysis by ICTU, and the results are anticipated to be published later this year.  

Dr Katerina Spranger, the CEO and founder of Oxford Heartbeat said, “this trial is so exciting because it is the first in the field where the data is collected in a real-world prospective setting to demonstrate objective and measurable benefits that PreSize brings to patients and clinical teams.” 

Publication of the trial results will position PreSize as the only software of its kind to have the highest Level 1 evidence, according to the American Journal of Neuroradiology (AJNR) guidelines. Therefore, the endorsed, prospective, clinical impact trial of PreSize will set a new standard for evidence generation regarding the use of decision-support software to support clinical decision making in neurovascular surgery and beyond. 

Dr Patankar explained the impact going forward, adding that “ESMINT endorsement will increase the visibility of the trial across the European neurovascular community, opening the door for wider collaboration, support, and adoption of the technology in clinical practice.”

Note to editors

About Oxford Heartbeat
Oxford Heartbeat’s vision is a world where every patient and doctor is supported by the most advanced technologies, and successful surgical outcomes are the norm, not the exception. We are transforming this vision into reality by providing clinicians with the cutting-edge technology they need to make life-saving decisions in preparing and executing high-risk surgeries. We strive to be innovative, rigorous, transparent and caring, putting clinicians and patients at the heart of everything we do.
About PreSize® Neurovascular
CE-marked software, PreSize® Neurovascular, helps interventional neuroradiologists (INRs) to prepare for minimally invasive brain stenting procedures. High levels of risk and inadequate technologies currently used in these surgeries mean that implants/stents are fitted in the patients’ anatomies based on a large amount of guesswork. PreSize® was designed to rectify these problems and help clinicians better prepare and execute surgeries in a more accurate way. INRs import patient scans into PreSize® and position the implant device into the reconstructed virtual blood vessel model. PreSize® generates a best-fit implant given patient anatomy, and INRs can explore different stent sizes/makes in a safe virtual setting, making adjustments to their satisfaction before operating. Thus the best-fit device is selected the first time round, reducing surgical complications and improving patient outcomes. The CE-marked software has undergone rigorous testing, with published studies showing that it can be reliably used to inform clinical decisions with high levels of accuracy and positively impact clinical decision making.